Search clinical trials for: Resectable Esophageal Cancer

Total 89079 results

Sichuan University

Recruiting

Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer

Esophageal Cancer

China
Tongji University

Recruiting

Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma

Esophageal Cancer

China
Royal Marsden NHS Foundation Trust
Gilead Sciences

Not yet recruiting

Peri-operative Zimberelimab (Anti-PD-1) vs Zimberelimab in Combination With Domvanalimab (Anti-TIGIT) in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric and Gastro-oesophageal Junctional Adenocarcinoma (ZODIAC) (ZODIAC)

Metastatic Gastric Cancer | Metastatic Esophageal Cancer
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer

Locally Advanced Unresectable Gastric Adenocarcinoma

China
Fujian Medical University Union Hospital

Not yet recruiting

Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer

Immunotherapy;Envafolimab; Esophageal Cancer
VA Office of Research and Development
VA Palo Alto Health Care System; VA Puget Sound Health Care System; Michael E... and other collaborators

Not yet recruiting

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Carcinoma

United States
Blokhin's Russian Cancer Research Center

Recruiting

The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer

Esophageal Cancer

Russian Federation
Zhejiang Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC (WATCHER)

Esophageal Squamous Cell Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Carcinoma

China
Fudan University

Recruiting

Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005) (ECTOP-2005)

Esophageal Cancer

China
Shandong Cancer Hospital and Institute

Recruiting

Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.

Advanced Esophageal Squamous Cell Cancer

China
Second Affiliated Hospital, School of Medicine,...
Hangzhou Neoantigen Therapeutics Co., Ltd.

Recruiting

Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection

Resectable Esophageal Cancer

China
Academisch Medisch Centrum - Universiteit van Amsterdam...

Recruiting

TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer (TRAP-2)

Esophageal Cancer | Esophageal Adenocarcinoma

Netherlands
The First Affiliated Hospital of Zhengzhou University

Recruiting

A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC

Esophageal Cancer

China
Chang Gung Memorial Hospital

Recruiting

To Observe the Benefit of Adding Brachytherapy After CCRT on Resectable Esophageal Cancer Patients Without Surgery

Esophageal Cancer

Taiwan
Fujian Cancer Hospital
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (REVO)

Esophageal Neoplasms | Esophageal Squamous Cell Carcinoma

China
Shanghai Zhongshan Hospital
Zhejiang Cancer Hospital; Sun Yat-sen University; Cancer Institute and Hospital... and other collaborators

Recruiting

Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC (iCROSS)

Esophageal Squamous Cell Carcinoma Stage II | Esophageal Squamous Cell Carcinoma Stage III

China
University Medical Center Mainz

Recruiting

RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial). (ROBOT-2)

Esophageal Adenocarcinoma

Germany
Henan Cancer Hospital

Recruiting

Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

Esophageal Cancer | Surgery | Survival | Neoadjuvant Treatment

China
Azienda Ospedaliera Universitaria Integrata Verona

Not yet recruiting

A Biomarker-driven Therapeutic Strategy for Esophageal Cancer Chemoradiotherapy in Patients With Resectable Adenocarcinoma of the ESophagus and Esophagogastric Junction (BoRgES)

Esophageal Cancer
Asan Medical Center

Recruiting

Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers (NeoChance)

Subjects With Resectable and Localized Gastric Cancer | Subjects With Resectable Esophageal Cancer or Liver Cancer | Subjects With Resectable Liver Cancer

Korea, Republic of
Henan Cancer Hospital

Recruiting

Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903) (HCHTOG1903)

Esophageal Squamous Cell Carcinoma

China
University of Colorado, Denver
National Cancer Institute (NCI)

Recruiting

Induction FLOT With CROSS CRT for Esophageal Cancer

Adenocarcinoma of the Gastroesophageal Junction | Adenocarcinoma Esophagus

United States
The Netherlands Cancer Institute
Hoffmann-La Roche

Recruiting

Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA) (PANDA)

Stomach Cancer | Gastro Esophageal Junction Cancer

Netherlands
Zhejiang Cancer Hospital

Recruiting

Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma (Neo-DRATEC)

Surgery | Esophageal Carcinoma | Neoadjuvant Chemoradiotherapy

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

Gastric Adenocarcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage 0 Gastric... and other conditions

United States
Apexigen America, Inc.

Completed

APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers

Esophageal Cancer | GastroEsophageal Cancer

United States
Centre Oscar Lambret
National Cancer Institute, France

Completed

PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer (PROTECT)

Esophageal Neoplasms | Gastro-esophageal Junction Cancer

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Nutritional Supplementation in Reducing Complications in Patients With Locally Advanced Esophageal Cancer Undergoing Chemotherapy, Radiation Therapy, and/or Surgery

Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Esophageal Adenocarcinoma... and other conditions

United States
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Active, not recruiting

Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 and other conditions

United States
Tang-Du Hospital

Completed

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

Sintilimab and Anlotinib in Combination With Chemotherapy

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Active, not recruiting

Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC (LEO)

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease

China
Jiangsu Cancer Institute & Hospital

Active, not recruiting

Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ (RARE)

Gastric or Gastroesophageal Junction Adenocarcinoma

China
BeiGene

Active, not recruiting

Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma

Resectable Esophageal Squamous Cell Carcinoma

China
University of Alabama at Birmingham
Aventis Pharmaceuticals; Pharmacia and Upjohn

Completed

Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer

Esophageal Cancer | Cancer of the Esophagus | Esophageal Neoplasm | Esophagus Cancer | Cancer of Esophagus

United States
University of Kansas Medical Center
Merck Sharp & Dohme LLC

Active, not recruiting

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Adenocarcinoma | Stomach Cancer | Gastro Esophageal Junction Cancer

United States
Yuhong Li

Completed

Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital with Nanjing Medical...
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
University of Wisconsin, Madison

Active, not recruiting

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

Resectable Esophageal Cancer | GastroEsophageal Cancer

United States
Zhejiang Cancer Hospital

Active, not recruiting

Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
SCRI Development Innovations, LLC
Aventis Pharmaceuticals; Sanofi-Synthelabo

Completed

Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer

Esophagus Cancer

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...

Completed

Chemoradiation and Panitumumab for Esophageal Cancer

Adenocarcinoma | Esophageal Cancer | Squamous Cell Carcinoma | Gastro-esophageal Junction Cancer

Netherlands
Peking University

Withdrawn

Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Per Pfeiffer

Completed

Chemotherapy for Patients With Cancer of the Stomach (DOS)

First-line Treatment for Patients With Non-resectable Gastric Cancer or Cancer of the Esophagus or

Denmark
Odense University Hospital
Aarhus University Hospital; Rigshospitalet, Denmark; Aalborg University Hospital

Completed

Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer

Adenocarcinoma

Denmark
Shanghai Zhongshan Hospital
Ruijin Hospital; Tianjin Medical University Cancer Institute and Hospital; Shanghai... and other collaborators

Completed

Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC (ESCCNCRTvNCT)

Esophageal Squamous Cell Carcinoma Stage cT3-4aN0-1M0

China
Academisch Medisch Centrum - Universiteit van Amsterdam...
UMC Utrecht

Completed

PDL-1 Targeting in Resectable Oesophageal Cancer (PERFECT)

Esophageal Cancer, Stage II | Esophageal Cancer Stage III

Netherlands
University Hospital Schleswig-Holstein

Completed

Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer

Esophageal Cancer

Germany
Jianhua Fu

Unknown

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Resectable Esophageal Cancer | Esophageal Squamous Cell Carcinoma by AJCC V8 Stage

China

Search clinical trials for: Resectable Esophageal Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations